CC-90006

DRUG2 trials

Sponsors

Celgene

Conditions

Healthy VolunteersPsoriasis

Phase 1

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects

CompletedNCT02934269

CelgeneHealthy Volunteers

Start: 2016-11-21End: 2017-08-15Updated: 2018-02-08

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

CompletedNCT03337022

CelgenePsoriasis

Start: 2018-01-04End: 2019-04-26Updated: 2020-05-07